An investigation has commenced into the fairness of the 2021 de-SPAC merger of NRx Pharmaceuticals Inc. (f/k/a Big Rock Partners Acquisition Corp.) (“NRXP” or the "Company") (NASDAQ: NRXP) . Shortly after the NRXP 2021 de-SPAC merger closed, NRXP stock began spiraling downwards.
The NRXP de-SPAC merger investigation concerns this transaction unfairly harmed stockholders and whether all material facts were properly disclosed to stockholders.
To receive more information, please fill out the form.